Obesity Market
- All
- News
- Videos
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
From Obesity To Rising Healthcare Costs, Why India Needs An Urgent War On Junk Food
The Economic Survey 2025-26 highlights ultra-processed foods as a public health concern linked to chronic diseases, obesity, and health inequalities, urging timely policy action.
-
Ban Advertising Of Ultra-Processed Foods From 6 Am-11 Pm: Economic Survey
Raising concerns on the growing consumption of ultra-processed foods containing high fat, salt and sugar amid India becoming one of the fastest growing markets for such items in the world, the Economic Survey has pitched for a ban on their ads.
-
Obesity Rising At Alarming Rate, Unhealthy Diets And Lifestyle Changes Responsible: Economic Survey 2025-26
Obesity is rising at an alarming rate and is today a major public health challenge in India, said Economic Survey for 2025-26 on Thursday.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
Weight Loss Ad Sparks Controversy: "Don't Promote Obesity, It's A lifestyle Disease," Say Experts
Obesity is a common risk factor for several serious health conditions like diabetes, heart disease, hypertension, fatty liver and others.
-
Mounjaro: Everything You Need To Know About This Medication
Read on as we discuss everything you need to know about this medication.
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
From Obesity To Rising Healthcare Costs, Why India Needs An Urgent War On Junk Food
The Economic Survey 2025-26 highlights ultra-processed foods as a public health concern linked to chronic diseases, obesity, and health inequalities, urging timely policy action.
-
Ban Advertising Of Ultra-Processed Foods From 6 Am-11 Pm: Economic Survey
Raising concerns on the growing consumption of ultra-processed foods containing high fat, salt and sugar amid India becoming one of the fastest growing markets for such items in the world, the Economic Survey has pitched for a ban on their ads.
-
Obesity Rising At Alarming Rate, Unhealthy Diets And Lifestyle Changes Responsible: Economic Survey 2025-26
Obesity is rising at an alarming rate and is today a major public health challenge in India, said Economic Survey for 2025-26 on Thursday.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
Weight Loss Ad Sparks Controversy: "Don't Promote Obesity, It's A lifestyle Disease," Say Experts
Obesity is a common risk factor for several serious health conditions like diabetes, heart disease, hypertension, fatty liver and others.
-
Mounjaro: Everything You Need To Know About This Medication
Read on as we discuss everything you need to know about this medication.
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
